Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Created:

December 11, 2020

News organization:

Rocket Pharmaceuticals

Link to news item:

https://www.businesswire.com/news/home/20201113005176/en/Rocket-Pharmaceuticals-Receives-Funding-from-the-California-Institute-for-Regenerative-Medicine-for-Phase-1-Clinical-Trial-of-RP-L401-for-Infantile-Malignant-Osteopetrosis

News type:

Press release